EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01774513

Enrollment

Registered

2013-01-24

Start date

2013-01-31

Completion date

Unknown

Last updated

2013-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Autoimmune Pancreatitis

Brief summary

The goal of this prospective study is to evaluate the feasibility of the Core Biopsy Needle with reverse bevel (Procore TM) in diagnosing autoimmune pancretitis

Interventions

DEVICEProcore-Needle

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patient age 18 years and older * patients with suspicion of autoimmune pancreatitis (based on the findings in EUS and MRI)

Exclusion criteria

* unable to obtain informed consent * ASA class 4 and 5 * known pregnancy * contraindication for endoscopy or for biopsy sampling * patients with high suspicion on pancreatic cancer (based on the findings in radiology and EUS)

Design outcomes

Primary

Measure	Time frame	Description
diagnostic yield	6 months	Number of patients with adequate tissue sample (which allows definitive diagnosis)

Countries

Germany

Contacts

Primary ContactStefan von Delius, MD

stefan_ruckert@yahoo.de

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026